Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Nutr Metab Cardiovasc Dis
; 23(9): 799-807, 2013 Sep.
Article
em En
| MEDLINE
| ID: mdl-23932901
Palavras-chave
ACCORD; AIM-HIGH; ARBITER; Action to Control Cardiovascular Risk in Diabetes; Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol; Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes; BIP; Bezafibrate Infarction Prevention; CTT; Cardiovascular diseases; Cholesterol Treatment Trialists; EAS; ERASE; ESC; Effect of reconstituted HDL on Atherosclerosis-Safety and Efficacy; European Atherosclerosis Society; European Society of Cardiology; FIELD; Fenofibrate Intervention and Event Lowering in Diabetes; Fibrates; HPS2-THRIVE; Heart Protection Study 2: Treatment of HDL to Reduce the Incidence of Vascular Events; Hypertriglyceridaemia; ILLUMINATE; Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events; Nicotinic acid; SCORE; Statins; Study of the Effect of Dalcetrapib on Atherosclerotic Disease in Patients with Coronary Artery Disease; Systemic Coronary Risk Estimation; Triglycerides; dal-OUTCOMES
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Triglicerídeos
/
Doenças Cardiovasculares
/
Inibidores de Hidroximetilglutaril-CoA Redutases
/
HDL-Colesterol
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article